SC
DYN icon

Stephens Consulting’s Dyne Therapeutics DYN Stock Holding History

Stephens Consulting’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35
Closed -$367 – 1426
2025
Q1 		$367 Buy
+35
New +$501 ﹤0.01% 1221

Other funds holding DYN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stephens Consulting's DYN Position: Q2 2025 in Review

Stephens Consulting sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 35 shares — an estimated $367 sold.

Stephens Consulting first reported a position in DYN in Q1 2025 and held it in 1 quarter. The position peaked at $367 in Q1 2025. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

  • Stephens Consulting reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 35 Dyne Therapeutics shares in Q2 2025, an estimated $367.
  • Stephens Consulting first reported a position in Dyne Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Dyne Therapeutics position peaked at $367 in Q1 2025.
  • 197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.